Gene Expression in Melanoma Tissues and Its Effects on the Malignant Biological Functions of Melanoma Cells

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Dec 19

PMID 39697757

Authors

Jiaojiao Qu

Xianfeng Cheng

Mingyan Liu

Qiang Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The catenin delta 2 () gene has been implicated in the progression of various cancers, but its specific role in melanoma has not yet been thoroughly investigated. This study sought to explore the expression and biological function of in malignant melanoma tissues to identify new targets or biomarkers for melanoma diagnosis and treatment.

Methods: Immunohistochemistry was used to examine the levels of in melanoma and adjacent non-tumor tissues. A Western blot analysis was performed to quantify the expression levels of in human immortalized keratinocytes and melanoma cell lines. The Cell Counting Kit-8 (CCK-8) assay, plate colony formation assay, cell adhesion assay, scratch test, and Transwell assay were used to assess the effects of knockdown on the proliferation, adhesion, migration, and invasion of melanoma cells. The Harmonizome database was used to research the biological processes (BPs) involved in .

Results: In the melanoma tissues, expression was substantially upregulated and its levels were closely linked with the pathological features of patients. The levels were notably more increased in the melanoma cell lines than the immortalized keratinocytes. The suppression of the gene substantially impeded the capacity of the melanoma cells to proliferate, migrate, and invade, and also significantly decreased their potential to attach to collagen I and IV, and fibronectin. The Harmonizome database results revealed a strong correlation between the BPs controlled by and the focal adhesion signaling pathway of the cells. The inhibition of the gene in melanoma cells resulted in a significant decrease in the phosphorylation of focal adhesion kinase (FAK) and the production of paxillin protein. In the melanoma cells, the reduction of did not have a significant effect on the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. However, it did considerably prevent the activation of mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) and its downstream molecule extracellular signal-regulated protein kinase 1/2 (ERK1/2).

Conclusions: The expression of the gene is increased in melanoma tissues, which enhances the ability of melanoma cells to proliferate both and . Additionally, the gene is crucial in controlling the adhesion process of melanoma cells. This mechanism is associated with the regulation of the FAK and MEK1/2/ERK1/2 signaling pathways. Based on our findings, could be used as an oncogene target for melanoma and a new treatment target or diagnostic biomarker.

References

Chauhan A, Khan T . Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors. Chem Biol Drug Des. 2020; 97(3):774-794. DOI: 10.1111/cbdd.13808. View

Zhang L, Zhao D, Wang Y, Zhang W, Zhang J, Fan J . Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network. Mol Carcinog. 2020; 60(2):113-124. DOI: 10.1002/mc.23273. View

Dawson J, Serrels A, Stupack D, Schlaepfer D, Frame M . Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021; 21(5):313-324. PMC: 8276817. DOI: 10.1038/s41568-021-00340-6. View

Tan X, Yan Y, Song B, Zhu S, Mei Q, Wu K . Focal adhesion kinase: from biological functions to therapeutic strategies. Exp Hematol Oncol. 2023; 12(1):83. PMC: 10519103. DOI: 10.1186/s40164-023-00446-7. View

Li H, Gao Y, Ren C . Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer. Discov Oncol. 2022; 12(1):29. PMC: 8777525. DOI: 10.1007/s12672-021-00425-6. View

Yang X, Yao B, Niu Y, Chen T, Mo H, Wang L . Corrigendum to hypoxia-induced lncRNA EIF3J-AS1 accelerates hepatocellular carcinoma progression via targeting miR-122-5p/CTNND2 axis. Biochem Biophys Res Commun. 2021; 565:101-102. DOI: 10.1016/j.bbrc.2021.04.109. View

Panera N, Crudele A, Romito I, Gnani D, Alisi A . Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. Int J Mol Sci. 2017; 18(1). PMC: 5297733. DOI: 10.3390/ijms18010099. View

Mitsos P, Anastasiou I, Constantinides C, Deligiannis D, Katafigiotis I, Papakonstantinou A . Clinical Importance of Focal Adhesion Kinase (FAK)-Src and Paxillin Expression in Renal Cell Carcinoma. Cureus. 2024; 16(6):e62706. PMC: 11259196. DOI: 10.7759/cureus.62706. View

Fujisaki H, Futaki S . Epithelial-Mesenchymal Transition Induced in Cancer Cells by Adhesion to Type I Collagen. Int J Mol Sci. 2023; 24(1). PMC: 9820580. DOI: 10.3390/ijms24010198. View

10.

Pang X, Liu X, Liu Y, Liu W, Li Y, Yu G . Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. Molecules. 2021; 26(14). PMC: 8308130. DOI: 10.3390/molecules26144250. View

11.

Lu Q, Aguilar B, Li M, Jiang Y, Chen Y . Genetic alterations of δ-catenin/NPRAP/Neurojungin (CTNND2): functional implications in complex human diseases. Hum Genet. 2016; 135(10):1107-16. PMC: 5021578. DOI: 10.1007/s00439-016-1705-3. View

12.

Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F . Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022; 158(5):495-503. PMC: 8968696. DOI: 10.1001/jamadermatol.2022.0160. View

13.

Huang B, Han W, Sheng Z, Shen G . Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients. Cancer Cell Int. 2020; 20:195. PMC: 7249670. DOI: 10.1186/s12935-020-01271-2. View

14.

Ripamonti M, Wehrle-Haller B, de Curtis I . Paxillin: A Hub for Mechano-Transduction from the β3 Integrin-Talin-Kindlin Axis. Front Cell Dev Biol. 2022; 10:852016. PMC: 9016114. DOI: 10.3389/fcell.2022.852016. View

15.

Abu-Elneel K, Ochiishi T, Medina M, Remedi M, Gastaldi L, Caceres A . A delta-catenin signaling pathway leading to dendritic protrusions. J Biol Chem. 2008; 283(47):32781-91. DOI: 10.1074/jbc.M804688200. View

16.

Chopra A, Sharma R, Rao U . Pathology of Melanoma. Surg Clin North Am. 2019; 100(1):43-59. DOI: 10.1016/j.suc.2019.09.004. View

17.

Lee B, Timpson P, Horvath L, Daly R . FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2014; 146:132-49. DOI: 10.1016/j.pharmthera.2014.10.001. View

18.

Zhang Y, Liu S, Zhou S, Yu D, Gu J, Qin Q . Focal adhesion kinase: Insight into its roles and therapeutic potential in oesophageal cancer. Cancer Lett. 2020; 496:93-103. DOI: 10.1016/j.canlet.2020.10.005. View

19.

Siegel R, Giaquinto A, Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):12-49. DOI: 10.3322/caac.21820. View

20.

Quispe P, Lavecchia M, Leon I . Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence. Drug Discov Today. 2021; 27(2):664-674. DOI: 10.1016/j.drudis.2021.11.025. View